The Capillary Morphogenesis Gene 2 (CMG2) gene encodes an Anthrax toxin receptor (ANTXR2), but the normal physiological function is not known. ANTXR2/ CMG2 was originally identified as a result of up-regulation during capillary morphogenesis of endothelial cells (ECs) cultured in vitro. We explored the hypothesis that key steps of the angiogenic process are either dependent or are influenced by ANTXR2/CMG2 activity. We describe the expression pattern of ANTXR2/CMG2 in several murine tissues and in normal breast and breast tumors. Endothelial expression was found in all of the tissues analyzed, in cultured ECs and in breast tumor vessels; however, ANTXR2/CMG2 expression was not restricted to this cell type. To assess potential angiogenic function, we used RNA interference to achieve significant reduction of ANTXR2/ CMG2 expression in cultured human umbilical venous endothelial cells (HUVECs). Reduced ANTXR2/CMG2 expression resulted in significant inhibition of proliferation and reduced capacity of ECs to form capillary-like networks in vitro, whereas overexpression of ANTXR2/ CMG2 in HUVEC increased proliferation and capillarylike network formation. Little change in migration of ECs was observed on knockdown or overexpression. We conclude that ANTXR2/CMG2 functions to promote endothelial proliferation and morphogenesis during sprouting angiogenesis, consistent with the endothelial expression of ANTXR2/CMG2 in several vascular beds.
Introduction
Angiogenesis, the process by which new blood vessels are derived from pre-existing vessels, is essential for physiological processes such as embryonic development, female reproduction, wound healing, and pathological processes such as tumor growth, atherosclerosis, and diabetic retinopathy (Carmeliet and Jain, 2000) . The mechanism of angiogenesis is often divided into distinct cellular phases to facilitate the study of this complex process. During the initial phase, endothelial cells (ECs) are stimulated to degrade and invade the underlying basement membrane and interstitial matrix. The cells then proliferate and migrate to form cord-like structures. Finally, differentiation occurs in which vessel lumens are formed, new basement membranes are produced, and accessory cells are recruited to stabilize new vessels (reviewed in Risau, 1997; Armulik et al., 2005; Adams and Alitalo, 2007) . An understanding at the molecular level as to how ECs assemble into new vessels is not fully understood, but depends on several angiogenic signaling pathways derived from cell surface receptors, such as the vascular endothelial growth factor (VEGF) receptors. In vitro assays designed to model the distinct steps of angiogenesis have proven useful in elucidating potential angiogenic regulators. For example, genes involved in capillary morphogenesis have been discovered using an EC morphogenesis assay in which ECs are suspended as individual cells in 3D collagen matrices (Bell et al., 2001) . Capillary Morphogenesis Gene 2 (CMG2) was originally identified in this manner. CMG2 was shown to be a gene with dramatically up-regulated expression in cultured human umbilical venous endothelial cells (HUVECs) induced to undergo capillary morphogenesis in vitro (Bell et al., 2001 (Scobie et al., 2003) . CMG2 489 and CMG2 488 are thought to reside at the cell surface as they contain signal sequences and are type I membrane proteins, but they differ as CMG2 488 has an alternate 13 amino acids at the C-terminus. These two isoforms contain an extracellular region with a von Willebrand factor type A (vWF) domain, a transmembrane domain, and a cytosolic tail of unknown function. The vWF domain contains a metal ion-dependent adhesion site consisting of five amino acid residues (DXSXSyTyD; where X can be any amino acid) that chelates a divalent cation critical for ligand binding (Shimaoka et al., 2002) . vWF domains are known to facilitate protein-protein interactions when found on extracellular matrix constituents or cell adhesion proteins like a-integrin subunits and are thought to constitute ligand-binding sites on CMG2. CMG2 386 is also a transmembrane protein, but it has been shown to reside at the endoplasmic reticulum membrane (Bell et al., 2001) . It is identical in amino acid composition to CMG2 489 except that it lacks 100 amino acids between the vWF domain and the transmembrane domain. CMG2 322 is predicted to contain a signal peptide and vWF domain identical to CMG2 489 , but as CMG2 322 lacks a transmembrane domain, this protein is predicted to undergo secretion.
Physiological receptor activity for CMG2 remains unknown given that there are no immediately recognizable signaling domains in the cytosolic tails. However, it is known that mutations in the CMG2 gene result in the human autosomal recessive syndromes, juvenile hyaline fibromatosis, and infantile systemic hyalinosis (Hanks et al., 2003) . These syndromes are characterized by recurrent subcutaneous tumors, gingival hypertrophy, joint contractures, osteolysis, osteoporosis, and hyaline depositions. The cellular basis of these related diseases and the degree of CMG2 loss of function due to mutations in affected individuals are currently not well understood. Finally, independent of the discovery of the gene being expressed during capillary morphogenesis and its association with a human disease, CMG2 has been revealed to encode a cellular receptor responsible for binding anthrax toxin. Therefore, it is also referred to as anthrax toxin receptor 2, or ANTXR2 (Scobie et al., 2003) . ANTXR2/CMG2 is one of the two receptors known to bind anthrax toxin, the other being ANTXR1 (Bradley et al., 2001) , which is encoded by a gene originally referred to as Tumor Endothelial Marker 8 (TEM8), based on expression in tumor endothelium (St Croix et al., 2000) .
The significance of anthrax toxin binding in relation to endogenous receptor activity for ANTXR2/CMG2 remains unknown due to the fact that endogenous receptor function is not defined. However, there is growing evidence to support the idea that ANTXR2/ CMG2 may be a gene whose protein product regulates angiogenesis. As mentioned earlier, ANTXR2/CMG2 was identified as a gene with dramatically up-regulated expression in cultured HUVEC induced to undergo capillary morphogenesis (Bell et al., 2001) . Furthermore, extracellular matrix proteins such as type IV collagen and laminin may be endogenous ligands for the receptor (Bell et al., 2001) . Both of these extracellular proteins are components of vessel basement membranes and type IV collagen is critical for capillary formation in vitro (Bell et al., 2001) . Thus, interaction between ANTXR2/ CMG2 and its native ligands may be important during angiogenic events. In addition, ANTXR2/CMG2 is closely related to the other ANTXR, ANTXR1/ TEM8. TEM8 splice variant 1 and CMG2 489 share 40% amino acid identity throughout their sequence and 60% identity within their vWF domains (Scobie et al., 2003) . Studies in support of an angiogenic function for ANTXR1/TEM8 have recently been published (St Croix et al., 2000; Carson-Walter et al., 2001; Hotchkiss et al., 2005; Rmali et al., 2005) . Briefly, ANTXR1/TEM8 has been identified as a gene specifically up-regulated in tumor versus normal endothelium (St Croix et al., 2000) . Furthermore, in vitro assays have been used to establish that ANTXR1/TEM8 expression is important for endothelial migration on type I collagen matrices (Hotchkiss et al., 2005) and tubule formation on matrigel (Rmali et al., 2005) .
Taken together, the data described earlier indicate that both ANTXR2/CMG2 and ANTXR1/TEM8 may be involved in physiological and pathological angiogenesis. As ANTXR2/CMG2 is expressed at higher levels in murine tissues than ANTXR1/TEM8 (Xu et al., 2007) and has higher binding affinity for anthrax toxin (Scobie et al., 2005) , we have chosen to focus on the potential function of ANTXR2/CMG2 in angiogenesis and the endothelium. To test the hypothesis that ANTXR2/CMG2 is an angiogenic regulator, we performed an immunohistochemical survey of ANTXR2/CMG2 expression in a variety of normal mouse tissues and normal and malignant human breast tissues. We also assessed cellular function of ANTXR2/CMG2 in vitro. We establish that ANTXR2/ CMG2 is expressed on murine and human vasculature in vivo and that ANTXR2/CMG2 is an angiogenic regulator critical for endothelial proliferation and capillary morphogenesis.
Results
ANTXR2/CMG2 is expressed in ECs of murine skin, colon, lung, and human breast tissue ANTXR2/CMG2 expression has been documented at the transcript level in a variety of human tissues (Hanks et al., 2003; Scobie et al., 2003) ; however, careful assessment of ANTXR2/CMG2 expression by immunohistochemistry has not been reported. Earlier studies suggest, but do not document, that ANTXR2/CMG2 is expressed on mammalian blood vessels. For instance, it has been reported that cultured HUVEC express endogenous ANTXR2/CMG2 (Bell et al., 2001) . To characterize the tissue specific and cellular distribution of ANTXR2/CMG2, we performed immunohistochemistry on a variety of normal mouse tissues using a chicken anti-CMG2 antibody that was raised against amino acids 1-232 of the human ANTXR2/CMG2 protein. We predicted that the antibody would detect ANTXR2/CMG2 in the mouse tissues analyzed as human and mouse ANTXR2/CMG2 are 93% identical at the amino acid level within the region recognized by the antibody. This antibody is specific for ANTXR2/ CMG2 and does not detect the related ANTXR1/TEM8 protein (Scobie et al., 2006) . A control experiment, performed with the batch of antibody used in this study, confirmed that it bound to ANTXR2/CMG2, and not to ANTXR1/TEM8, when these proteins were expressed on the surfaces of ANTXR-deficient CHO-R1.1 cells (Figure 1a) .
We proceeded to characterize ANTXR2/CMG2 expression in tissues that represent the main routes of entry for anthrax toxin into the body: skin, lung, and intestine (Mock and Mignot, 2003) . Immunofluorescence on mouse skin revealed that ANTXR2/CMG2 is expressed in the keratinocytes of the epidermis, in the outer root sheath of telogen hair follicles, on smooth muscle cells, and in the vascular endothelium (Figures 1b-d and g ). ANTXR2/CMG2 expression in the epidermis was also confirmed at the transcript level through RT-PCR using cDNA from mouse primary keratinocytes (data not shown). As the epidermis is composed of proliferative and differentiated cell layers, we wanted to determine whether ANTXR2/CMG2 is expressed throughout all epidermal layers or whether expression is restricted to a particular layer(s). Therefore, the keratinocyte markers keratin K14 (proliferative) and involucrin (differentiated) were used in combination with ANTXR2/CMG2 to immunostain mouse skin. As expected, keratin K14 expression was detected in the basal layer of the epidermis and in the hair follicle outer root sheath (Figure 1e ) and involucrin was localized to the suprabasal layers of the epidermis (Figure 1h ). Co-staining mouse skin with ANTXR2/ CMG2 and either keratin K14 or involucrin established that ANTXR2/CMG2 localizes with both of the keratinocyte markers (Figures 1f and i) . Therefore, ANTXR2/CMG2 expression is not restricted to a particular layer of the epidermis, but seems to be expressed in all compartments. Immunostaining of mouse lung revealed that ANTXR2/CMG2 is highly expressed in the epithelial cells lining the aveoli, in the ciliated epithelial cells coating the bronchi, and in the vascular endothelium (Figure 2a) . Similarly, immunostaining of the colon revealed that ANTXR2/CMG2 is highly expressed in the epilthelial cells lining the villi and on the vascular endothelium (Figures 2c and e) . To confirm that ANTXR2/CMG2 is expressed on the vessels in these tissues, we compared ANTXR2/CMG2 expression with that of CD-31, an endothelial marker (Figures 2b, d, and f) . For all of the tissues stained, we observed no detectable signal when using secondary antibody alone (data not shown). We also performed blocking studies to confirm antibody specificity. The chicken anti-human CMG2 antibody was pre-incubated with 10-fold molar excess of purified recombinant human ANTXR2/CMG2 protein and then used to immunostain mouse lung, colon, and human skin. The immunostaining signal was greatly reduced in the epithelial cells lining the villi of mouse colon and the bronchioles of mouse lung as compared with unblocked antibody staining (Figures 2g and h ; Supplementary Figure 1 ). In addition, the highly positive signal on the epidermis of the skin and on the blood vessels from all of the tissues analyzed was lost under blocking conditions ( Figure 2h blow-up; Supplementary Figures  1a and b, 2a and b) . We conclude that ANTXR2/CMG2 is expressed in a variety of cell types in lung, intestine, and skin, and definitive expression on ECs was detected in each of these tissues.
The vasculature in the adult mouse tissues evaluated earlier is composed of quiescent endothelium. To determine whether ANTXR2/CMG2 is expressed on angiogenic vessels, we next compared normal (quiescent) and malignant (angiogenic) human breast tissue. Fresh frozen serial sections of normal human mammary tissue obtained from reduction mammoplasties were subjected to immunohistochemical staining with anti-CMG2, anti-type IV collagen, and anti-CD31 antibodies (Figures 3a-c) . ANTXR2/CMG2 expression was not detected in normal breast epithelium. However, the blood vessels (identified by CD31 staining) and basement membranes surrounding mammary ducts were clearly positive for ANTXR2/CMG2 (Figure 3a) . Moreover, the ANTXR2/CMG2 expression pattern was identical to that of type IV collagen, a predicted ligand for CMG2 (Figure 3b ). Type IV collagen is a known component of basement membranes.
Immunostaining serial sections of human breast cancer revealed that ANTXR2/CMG2 expression was localized to tumor basement membranes, tumor stroma, and microvessels throughout both the tumor and stroma, but was absent from the tumor cells ( Figure 3d ). The ANTXR2/CMG2 expression pattern matched that seen for type IV collagen (Figure 3e ) on vessel and tumor basement membranes. Furthermore, the ANTXR2/CMG2 staining pattern was lost in the presence of blocking peptide, confirming specificity of the antibody ( Supplementary Figures 2c and d) . Thus, in human tissue, CMG2 was found to be expressed on both quiescent and angiogenic vasculature and was found to co-localize with its ligand, type IV collagen.
ANTXR2/CMG2 expression is necessary for EC proliferation
The consistent expression of ANTXR2/CMG2 on ECs of mouse and human tissues supports the hypothesis that it may be important in angiogenesis or EC function. To further explore this potential function, we used a series of in vitro angiogenesis assays with HUVEC to define the role of ANTXR2/CMG2 during distinct steps of angiogenic progression. To assess function, ANTXR2/CMG2 expression was reduced in HUVEC using CMG2-specific RNAi expressed through retroviral vectors.
Retrovirally infected and puromycin selected HU-VEC lines were generated to express empty vector (HUVEC/control), scrambled shRNA, or shRNA targeting ANTXR2/CMG2 transcripts (HUVEC/ shCMG2). Similar results were obtained when using either empty vector or scrambled shRNA as the control cell line in a given experiment. The resulting cell lines were fixed and immunostained with chicken anti-human CMG2 antibody to evaluate ANTXR2/CMG2 protein levels. HUVEC/shCMG2 displayed reduced ANTXR2/ CMG2 expression at the protein level as compared with empty vector control (Figure 4a ). In addition, we observed reduced ANTXR2/CMG2 expression at the cell surface when the HUVEC lines were analyzed through flow cytometry with the ANTXR2/CMG2 antibody (Supplementary Figure 3a) . ANTXR2/ CMG2 knockdown was evaluated at the transcript level through real-time PCR. We found that retroviraldelivered shRNA efficiently suppressed ANTXR2/ CMG2 transcript expression in the HUVEC/shCMG2 lines from 30 to 85% as compared with control cell lines ( Figure 4b ).
Once ANTXR2/CMG2 knockdown was confirmed, the retroviral lines were used to examine the effect of reduced ANTXR2/CMG2 expression on EC proliferation. Equivalent numbers of empty vector control (HUVEC/control) and ANTXR2/CMG2 knockdown cells (HUVEC/shCMG2) were seeded on type I collagen-coated plates and cultured for 4 days in the presence of serum-free medium (SFM) supplemented with EGF and VEGF-A. Reduction of ANTXR2/ CMG2 expression led to a corresponding reduction in proliferation when compared with empty vector control (Figure 4c ). For example, a HUVEC/shCMG2 A line with 30% knockdown of ANTXR2/CMG2 at the transcript level had a 50% reduction in proliferation whereas a HUVEC/shCMG2 B line with 85% knockdown at the transcript level had a 70% reduction in proliferation. Thus, the pattern of reduction correlated with the level of transcript knockdown obtained for each cell line. Moreover, this effect was not due to differences in seeding efficiency between the two cell lines as determined by WST-8 readings 4 h after seeding (Supplementary Figure 3b) .
As an alternative measure of proliferation, we performed flow cytometry with propidium iodide stained cells to assess DNA content. The resulting histograms consisted of three-cell populations: those in G 0 /G 1 phase, S phase, and G 2 /M phase of the cell cycle. The histogram in Figure 4d is data from one experiment in which 60% of scrambled control cells were in G 0 /G 1 phase and 40% were in S and G 2 /M phase versus ANTXR2/CMG2 knockdown cells, which had 74% of cells in G 0 /G 1 phase and 25% of cells in S and G 2 /M phase. These data are one representative from six different experiments with six different cell lines in which the control cell lines had a higher proportion of dividing cells than the knockdown cell lines. Thus, the proliferation defect for ANTXR2/ CMG2 knockdown cells was confirmed by two different experimental means.
Reduced ANTXR2/CMG2 expression does not significantly affect EC migration We next evaluated whether EC migration is affected on reduced ANTXR2/CMG2 expression through a cellularwounding assay. Confluent monolayers of the retroviral HUVEC lines were disrupted with a pipet tip and EC migration into the stripped area was monitored over a 12-h time period. ANTXR2/CMG2 knockdown resulted in a slight decrease in the migration rates of HUVEC on type I collagen as compared with empty vector control ( Figure 5a) ; however, the magnitude of reduced migration in separate assays varied from undetectable to modest reduction. We obtained similar results when the cell lines were plated on the CMG2 ligand, type IV collagen (data not shown).
As proliferation is involved in cells re-occupying the wound during the cellular-wounding assay, we also wanted to evaluate chemokinesis through a random cell movement assay. In this assay, cells were seeded on type I collagen-coated slide wells and the movement of individual cells was recorded through time-lapse imaging over 10 h. The results from this assay showed little change in the average rate of cell movement between control cells and ANTXR2/CMG2 knockdown cells (Figure 5b ). The control HUVEC had a migration rate of 30.7 versus 27.4 mm/h for the ANTXR2/CMG2 knockdown HUVEC (P>0.2). Taken together, the results from the cellular-wounding and random cell movement assays show that reduced ANTXR2/CMG2 expression does not significantly affect EC migration/ movement.
ANTXR2/CMG2 expression is required for capillary-like network formation in vitro As ANTXR2/CMG2 gene expression has been reported to be up-regulated during capillary morphogenesis in vitro (Bell et al., 2001) , we assessed the effect of ANTXR2/CMG2 knockdown on their ability to organize into capillary-like networks or form lumen-containing tubes. To assess capillary-like network formation, the retroviral cell lines were seeded between two layers of porcine collagen gel and cultured in SFM supplemented with EGF and VEGF-A. The cells were photographed on day 4 of culturing. As shown in Figure 6a , the control cells formed a fine network of capillary-like cords. In contrast, ANTXR2/CMG2 knockdown inhibited VEGF-A-mediated capillary-like network formation (Figure 6a) . Quantification of the surface area covered by the networks showed that the formation of capillary-like structures was reduced by 50% in the knockdown cell line as compared with control ( Figure 6b ). Given that the cord structures formed during this assay rarely contain identifiable lumens, we also evaluated the effect of ANTXR2/ CMG2 knockdown in HUVEC induced to undergo capillary tube formation when the cells are embedded in an extracellular matrix composed of porcine collagen gel. In this assay, HUVEC cells arrange into lumen-containing capillary-like tubes (Bell et al., 2001) . We found that ANTXR2/CMG2 knockdown impaired HUVEC morphogenesis into such capillarylike tubes (Figure 6c ). Taken together, these data suggest that endogenous expression of ANTXR2/ CMG2 is necessary to make fine networks of neovessels using HUVEC.
CMG2 overexpression increases EC proliferation and capillary-like network formation but not migration
To compliment the loss-of-function approach taken above, we generated stable cell lines overexpressing ANTXR2/CMG2. HUVEC lines were generated by transduction with retrovirus encoding no protein or CMG2 489 fused to GFP (HUVEC/CMG2GFP). Fluorescent microscopy was used to verify overexpression of ANTXR2/CMG2 by checking the GFP-based fluorescence associated with the recombinant receptor. Although ANTXR2/CMG2 knockdown was found to decrease EC proliferation, overexpression of ANTXR2/ CMG2 increased cellular proliferation by almost 40% (Figure 7a ). As expected, cellular migration rates remained unchanged when ANTXR2/CMG2 was overexpressed (Figure 7b ). This was consistent with the observation that ANTXR2/CMG2 knockdown did not significantly affect EC migration. ANTXR2/ CMG2 overexpression did, however, increase the network of capillary-like cords formed in the sandwich network formation assay (Figure 7c) . Quantification of the surface area covered by the networks showed that the formation of capillary-like structures was increased by B50% on ANTXR2/ CMG2 overexpression as compared with control ( Figure 7d ). 
Discussion
ANTXR2/CMG2 was originally identified as a gene with up-regulated expression during capillary morphogenesis, suggesting a potential role in angiogenesis; however, little is known about its function. Here, we report analysis of the potential angiogenic function of ANTXR2/CMG2 using two approaches. First, we establish that ANTXR2/CMG2 is expressed in blood vessels found in several tissues, including murine skin, lung, colon, and normal and tumorigenic human breast tissue. Second, using in vitro assays, we report that ANTXR2/CMG2 knockdown diminishes EC proliferation and the ability to form capillary-like structures, whereas ANTXR2/CMG2 overexpression increases proliferation. We conclude that ANTXR2/CMG2 functions in EC proliferation and morphogenesis.
Angiogenic regulators are either widely expressed in many cell types or can be endothelial specific in their expression. The latter category includes proteins such as VEGFR-2 and VE-Cadherin, both of which are involved in angiogenesis and vascular integrity and these proteins primarily function in ECs. The two anthrax receptor genes, ANTXR2/CMG2 and ANTXR1/TEM8, were originally identified in ECs (St Croix et al., 2000; Bell et al., 2001) , and this suggested potential roles in angiogenesis. In the case of ANTXR1/ TEM8, original reports of tumor endothelial-specific expression have been supplemented with studies documenting expression in several cell types, including but not limited to endothelium (Carson-Walter et al., 2001; Bonuccelli et al., 2005) . Little was known regarding ANTXR2/CMG2 protein expression and thus we performed an immunohistochemical survey of mouse lung, colon, skin tissues, and normal and tumorigenic human breast tissue. We report that ANTXR2/CMG2 is widely expressed in a variety of cell types, including quiescent and angiogenic ECs (Figures 1-3) . Using histological analysis and staining with cell-specific markers, we show ANTXR2/CMG2 expression in blood vessels of skin (Figure 1 ), colon (Figure 2) , and lung (Figure 2 ). In dermis, strong expression was found on keratinocytes, which were identified both histologically and based on expression of keratin K14 and involucrin. In addition, we detected ANTXR2/CMG2 transcripts expressed in cultured keratinocytes (data not shown). In colon and lung, ANTXR2/CMG2 was also expressed in epithelial cells.
It is possible that the ANTXR2/CMG2 expression pattern detected in mouse tissues could reflect the combined expression pattern of ANTXR2/CMG2 and ANTXR1/TEM8, as our data and an earlier published report indicate that the two proteins are expressed in many of the same cell types. The peptide sequence used to raise the anti-human ANTXR2/CMG2 antibody shares B52% identity with mouse ANTXR1/TEM8. However, ANTXR2/CMG2 transcripts have been detected in all three of the mouse tissues we analyzed, and it has been reported that the ratios of ANTXR2/CMG2 to ANTXR1/TEM8 mRNA expression levels are 20:1 in the gastrointestinal tract and 4:1 in both the lung and skin (Xu et al., 2007) , indicating that ANTXR2/CMG2 may be the major ANTXR expressed. The immunohistochemical analysis performed on normal mouse tissues likely represents the expression pattern of ANTXR2/CMG2 when one considers the following: (1) blocking studies using a human ANTXR2/CMG2 blocking peptide reduced the signal in the mouse tissues and (2) the location of ANTXR2/CMG2 expression in mouse skin directly parallels its location in human skin, where crossreactivity with human ANTXR1/TEM8 does not occur.
It had been reported earlier that ANTXR1/TEM8 expression is specific to tumor endothelium as its expression was absent from quiescent endothelium in normal adult tissues (Nanda and St Croix, 2004) . This is not the case for ANTXR2/CMG2. Analysis of normal and malignant human breast tissue revealed that ANTXR2/CMG2 was expressed on both quiescent and angiogenic vessels (Figure 3) . In normal breast, ANTXR2/CMG2 was found in vessels of the stroma and in the basement membrane surrounding the epithelial ducts; however, expression was not seen in ductal epithelium. As in normal breast, basement membrane surrounding ductal carcinoma cells retained the ANTXR2/CMG2 expression. The tumor vessels that grew into the ductal carcinomas were clearly ANTXR2/ CMG2 positive. Furthermore, the ANTXR2/CMG2 expression pattern co-localized with that of type IV collagen, a putative ANTXR2/CMG2 ligand, in both normal and malignant human breast tissue. This is the first study showing receptor-ligand co-localization, suggesting that type IV collagen may in fact be an endogenous ligand for ANTXR2/CMG2.
On the basis of our immunohistochemical analyses, we conclude that ANTXR2/CMG2 is expressed in endothelium, kertinocytes, and a variety of other cell types. It is not known how ANTXR2/CMG2 may function in these diverse cell types, but it is clear that ANTXR2/CMG2 is expressed in several cells that come in contact with Bacillus anthracis, the causative agent of anthrax.
Given the expression of ANTXR2/CMG2 in endothelium of mouse and human tissues, we next explored ANTXR2/CMG2 function in ECs. We chose shRNAmediated knockdown of ANTXR2/CMG2 expression as a means of inhibiting ANTXR2/CMG2 activity. ECs with reduced ANTXR2/CMG2 expression were generated using RNA interference. An ANTXR2/CMG2 siRNA-specific decrease in transcript and protein levels was confirmed by real-time PCR and immunostaining of the retroviral cell lines (Figure 4) . The most striking effect of this reduced expression was the significant decrease in endothelial proliferation we observed in HUVEC. This effect was not previously suggested from analysis of ANTXR1/TEM8 function (Hotchkiss et al., 2005; Rmali et al., 2005) . ANTXR2/CMG2 knockdown also adversely affected the ability of ECs to form capillary-like networks in vitro. This assay depends on proper angiogenic signals to stimulate EC morphogenesis and branching. As shown in Figure 6 , reduced ANTXR2/CMG2 expression clearly disrupted capillary-like network and tube formation. As network formation is known to occur rapidly in these assays, we believe that this is a direct effect on the ability of ECs to form cords and tube-like structures. Finally, overexpression of ANTXR2/CMG2 was found to have the opposite effect of knockdown in that it promoted EC proliferation and network formation (Figure 7) . Thus, primary ECs depend on proper ANTXR2/CMG2 expression to undergo normal cell proliferation and capillary-like network formation-key steps in angiogenesis.
This is the first study to show that knockdown of ANTXR2/CMG2 expression strongly inhibits EC function in vitro. The mechanism by which ANTXR2/ CMG2 promotes these processes remains to be determined. However, given ANTXR2/CMG2 protein structure and ligand-binding capabilities, a likely mechanism involves modulating EC-extracellular matrix interactions. Additional support for this idea is provided by recently published data in which protective antigen (PA), the receptor-binding moiety of anthrax toxin, was used as a receptor antagonist. PA was shown to inhibit EC function in vitro and angiogenesis in vivo by interfering with the binding of ANTXR2/CMG2 or ANTXR1/TEM8 to their endogenous ligands, extracellular matrix proteins (Rogers et al., 2007) . Furthermore, characterization of the protein domains responsible for contributing to ANTXR1/TEM8 function revealed that the vWF and the transmembrane domains, as opposed to the intracellular portion of the protein, might be the domains necessary for promoting ANTXR1/TEM8 angiogenic (Rmali et al., 2005) . The vWF domain is thought to be the ligand-binding domain on ANTXR1/TEM8, thus protein/ECM interactions are hypothesized to be integral to ANTXR1/ TEM8 angiogenic function. Future work will determine whether the same holds true for ANTXR2/CMG2. Although ANTXR2/CMG2 and ANTXR1/TEM8 are closely related, their endogenous functions in ECs may be distinct from one another. Overexpression of ANTXR1/TEM8 has been shown to promote EC migration but not proliferation or network formation (Hotchkiss et al., 2005) . Antagonizing ANTXR1/TEM8 function, through the use of a secreted ANTXR1/TEM8 extracellular domain or through knockdown with hammerhead ribozymes, inhibited EC migration and network formation (Hotchkiss et al., 2005; Rmali et al., 2005) . In contrast, knockdown of ANTXR2/CMG2 resulted in strong inhibition of EC proliferation and network/tube formation, whereas overexpression of ANTXR2/CMG2 promoted proliferation and network formation. Neither knockdown nor overexpression of ANTXR2/CMG2 had an effect on migration. As such, ANTXR1/TEM8 may function in EC migration, whereas ANTXR2/CMG2 may function in proliferation and tube formation. If so, it will be interesting to explore how the two ANTXRs function in distinct EC behaviors. During preparation of this paper, an Antxr2/Cmg2 knockout mouse was reported on and found to be viable, indicating that developmental angiogenesis was not impaired on Antxr2/Cmg2 deletion (Liu et al., 2009) ; however, postnatal and pathological angiogenesis was not evaluated in this study. In light of this report, it is possible that Antxr1/Tem8 may compensate for lack of Antxr2/Cmg2 function in the mouse. Therefore, it will be informative to generate mice deficient in both Antxr1/Tem8 and Antxr2/Cmg2.
In conclusion, we have shown that ANTXR2/CMG2 is expressed on the vasculature in vivo and that ANTXR2/CMG2 functions to promote angiogenic processes. Our study makes it increasingly evident that ANTXR2/CMG2 is an angiogenic regulator. Future studies will help define the physiological and pathological function of these receptors in vasculature. For instance, one can determine whether tumor endothelium depends on proper activity of ANTXR2/ CMG2 to rapidly grow into an avascular cancerous tissue.
Materials and methods

DNA constructs and cell lines
ANTXR-deficient CHO-R1 cells engineered to express recombinant receptor-EGFP fusion proteins, CMG2 489 -EGFP or ATR/TEM8sv2-EGFP, have been described (Scobie et al., 2003) . CMG2 489 -EGFP fusion protein was engineered into retroviral vector pHyTCX. HUVECs were isolated from human umbilical vein as described earlier (Jaffe et al., 1973) and cultured in EGM2 Bullet kit medium (Lonza, Basel, Switzerland) on dishes coated with type I rat tail collagen (VWR, West Chester, PA, USA).
Cell surface receptor expression analysis Flow cytometry analysis of ANTXR2/CMG2 and ANTXR1/ TEM8 expression on the surface of transfected CHO cells has been described earlier (Scobie et al., 2006) .
Animals
This study was conducted according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Animal protocols were approved by the Institutional Animal Care and Use Committees. For all of the experiments, we used 6-week-old female wild-type mice in the C57BL/6 background. After the mice were killed, the lungs were removed and insufflated with 2 ml 10% neutrally buffered formalin. Colon samples and skin biopsies were surgically removed and fixed in 10% neutrally buffered formalin for 24 h, after which the samples were placed in 70% ethanol until processing. The tissue samples were paraffin embedded and 5-mm thick sections were cut and placed on Super-Frost Plus slides (Fisher, Waltham, MA, USA) for immunohistochemistry.
Colormetric IHC A measure of 5 mm serial paraffin sections were deparaffinized in xylene, hydrated through a graded series of ethanol washes and placed in phosphate-buffered saline (PBS). Antigen retrieval was performed by heating for 20 min in antigen retrieval solution (Dako, Carpinteria, CA, USA). Endogenous peroxide activity was quenched by incubation in 3% hydgrogen peroxide/methanol solution for 10 min. Endogenous biotin was blocked using the Avidin/Biotin blocking kit (Vector Laboratories, Burlingame, CA, USA). Before primary antibody application, tissue sections were blocked in PBS contain-ing 3% bovine serum albumin and 2% normal serum (Sigma, St Louis, MO, USA) matching to the secondary antibody. Primary antibodies were incubated for 1 h at room temperature. Primary antibodies used were chicken anti-human CMG2 (Scobie et al., 2006) and rat anti-mouse CD31 (BD Pharmingen, San Jose, CA, USA). Negative controls were left with blocking solution. Incubation with biotinylated secondary antibodies (Vector Laboratories), specific to each primary antibody was performed for 30 min at room temperature and followed by incubation with avidin and horseradish-peroxidase conjugated biotin in PBS (Vectastain Standard ABC Elite kit, Vector Laboratories). The color reaction was performed using DAB (diaminobenzidine tetrahydrochloride), the peroxidase substrate (Vector Laboratories). Tissues were counterstained with hematoxylin (Fisher).
Studies using human breast tissues were approved by Columbia University Institutional Review Board. A measure of 5mm serial sections of frozen human breast tissue were fixed in cold acetone before immunostaining. Before primary antibody incubation, tissues were blocked as indicated earlier.
Primary antibodies used were chicken anti-human CMG2 (Scobie et al., 2006) , mouse anti-human type IV collagen (Calbiochem, Darmstadt, Germany), and mouse anti-human CD31 (Dako). Secondary antibody incubation and color reaction was performed as indicated earlier.
Blocking experiments were performed by pre-incubating the chicken anti-human CMG2 antibody with 10-fold molar excess recombinant human CMG2 protein (Novus Biologicals, Littleton, CO, USA) for 2 h at room temperature before adding the antibody to slides. Images were obtained on Nikon ECLIPSE E 800 microscope (Nikon Inc., Melville, NY, USA).
Immunofluorescent IHC
Immunostaining was performed as described earlier until application of secondary antibodies. Primary antibodies used were chicken anti-human CMG2 (Scobie et al., 2006) , rabbit anti-keratin K14 (Covance, Denver, PA, a gift from Dr David Owens, Columbia University), and rabbit anti-Involucrin ( (Li et al., 2000) , a gift from Dr David Owens, Columbia University). Sections were incubated with biotinylated Alexa Fluor tagged secondary antibodies (Molecular Probes, Invitrogen, Carlsbad, CA, USA), which were specific to each primary antibody. DAPI (4 0 ,6-diamidino-2-phenylindole) (Sigma) was used to visualize nuclei.
ANTXR2/CMG2 gene silencing
Three different CMG2 siRNA oligos were purchased from Ambion (Austin, TX, USA) and screened through transient transfection and RT-PCR for adequate silencing of the ANTXR2/CMG2 gene. The sequence resulting in knockdown of ANTXR2/CMG2 transcripts was used to generate oligos that were cloned into pSIREN retroviral vector (BD Biosciences, San Jose, CA, USA) following the manufacturer's instructions. The siRNA target sense sequence was 5 0 -GCTAGCGAATGAACAAATTCA-3 0 . The resulting pSI-REN-shCMG2 plasmid was used to generate retroviral cell lines as described below. Successful silencing of the ANTXR2/ CMG2 gene was confirmed by real-time PCR as described below. pSIREN empty vector and pSIREN-scrambled shRNA were used as controls.
Gene transfer into HUVEC For retroviral gene transfer, the retroviral vector pSIREN or pHyTCX was used. GP293 packaging cells, 5 Â 10 6 (Clontech, Mountain View, CA, USA), were seeded and transfected with 10 mg pSIREN-empty vector, scrambled shRNA, CMG2
shRNA, pHyTCX or pHyTC-CMG2 489 GFP and 10 mg pVSVG. Retroviral-containing supernatants were collected after 48 h, filtered and added to low passage HUVEC. At 48 h after infection, pSIREN cell lines were selected for 5 days with puromycin (Invitrogen) at 3 mg/ml and then maintained at 1.5 mg/ml. pHyTCX infected cells were selected for 5 days with 300 mg/ml hygromycinB (Invitrogen). ANTXR2/CMG2 gene silencing and overexpression was confirmed through real-time PCR as described below.
Quantitative RT-PCR analysis Total RNA was isolated using RNeasy kit (Qiagen, Valencia, CA, USA) and first strand synthesis was performed using random hexamers and Superscript II reverse transcriptase (Invitrogen). 
Indirect immunocytochemistry
Cells seeded on type I collagen-coated coverslips were washed with PBS, fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and blocked with PBS containing 3% BSA and 2% serum. Cells were incubated with chicken anti-CMG2 antibody followed by incubation with Alexa Fluor 594-coupled secondary antibody (Invitrogen). Control cultures were incubated with secondary antibody alone. Coverslips were mounted with medium-containing DAPI (4 0 ,6 diamidino-2-phenylindole; Vectashield; Vector Laboratories). Cells were visualized on Nikon ECLIPSE E 800 microscope.
Proliferation assays in vitro
Low-passage HUVEC were infected with retrovirus, as described earlier. pSIREN-empty vector and pSIRENshCMG2 cells were seeded at 10 000 cells/well in SFM supplemented with 20 ng/ml EGF (Invitrogen) and 20 ng/ml VEGF-A165 (Research Diagnostics, Inc., Concord, MA, USA) on collagen-coated 24-well plates. Cell numbers were assessed 4 h after seeding and at day 4 with the Cell Counting Kit-8 assay (Dojindo Molecular Technologies, Gaithersburg, MD, USA) by preparing a calibration curve from known cell numbers, according to the manufacturer's instructions. All assays were performed in triplicate and repeated at least three times with three different cell lines.
Cell cycle analysis Cells (10 5 ) were plated on type I collagen-coated plates and cultured in complete medium. After 4 days, cells were trypsinized and counted. In all, 3 Â 10 5 cells were pelleted, washed once in PBS, and resuspended in 0.5 ml cell cycle staining solution (50 mg Propidium Iodide (Sigma Aldrich), 1 g NaCitrate (Fisher) in 1000 ml distilled water). Cells were incubated for 30 min at room temperature in the dark and maintained at 4 1C before flow cytometry analysis on FACS Calibur (BD Bioscience). Living cells were gated according to propidium iodide staining. Data were analyzed through CellQuest Software (Becton Dickinson, Franklin Lakes, NJ, USA). Six different control and knockdown cell lines were tested.
Capillary-like network formation assay Assays were performed as described earlier (Tung et al., 2009 ). All of the experiments were performed in triplicate and repeated at least three times with three different cell lines.
3D tube formation assay
Porcine collagen gel (Wako USA, Richmond, VA, USA) was prepared according to the manufacturer's instructions. Retrovirally infected HUVEC were resuspended in collagen gel at 1 Â 10 6 cells per 1 ml collagen gel and the cell/gel mixture was aliquoted 100 ml per well into 24-well plates. The cell/gel suspension was allowed to polymerize at 37 1C for 30 min. The cells were then cultured in SFM containing 40 ng/ml EGF (Invitrogen), 40 ng/ml bFGF (Invitrogen), and 40 ng/ml VEGF-A165 (Research Diagnostics Inc.). The cultures were photographed after 72 h. All of the experiments were performed in triplicate and repeated at least three times with three different cell lines.
Cell migration assays
For cellular-wound assays, retrovirally infected HUVEC were seeded to confluence on 24-well plates coated with type I collagen. After 24 h, the cell monolayer was stripped away with a pipet tip across the diameter of each well. The medium and dislodged cells were aspirated and washed with PBS. Complete medium was added to the plates, and cells were incubated at 37 1C. Migration into the stripped areas was photographed at 0 and 12 h time points. Visual assessment of the leading edge was made and marked accordingly for each time point. All of the experiments were performed in triplicate and repeated at least three times with three different cell lines.
For random cell movement assays, the cells were sparsely plated (5 Â 10 3 ) onto type I collagen (BD Biosciences) coated four-well slides and allowed to adhere for 1 h. Slides were then placed on a heated stage (37 1C) and nuclear positions were tracked from phase images captured every 20 min over 10 h on a Nikon TE300 microscope at Â 10 magnification. Cells that remained in the field of vision throughout the 10 h without dividing or dying were used for analysis. Metamorph imaging software (Molecular Devices, Downington, PA, USA) was used to determine the x and y coordinates for the nucleus of each tracked cell and these coordinates were measured in pixels from frame to frame to ascertain distance traveled between frames. Distance traveled between frames was then added to yield the total distance (in pixels) migrated by each cell during 10 h. These values were used to determine the average cellular speed of all the eligible cells in a group. Data are presented as average distance traveled in microns per hour (0.645 mm per pixel).
Statistical analysis
Statistical significance was evaluated using the unpaired Student's t-test with P-value o0.05 considered statistically significant.
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